摘要
目的比较GMEX系统即时检测(POCT)与传统血液检测方法用于细胞色素P4502C19(CYP2C19)基因分型的一致性,评估POCT技术快速指导高危非致残性缺血性脑血管事件(HR-NICE)患者氯吡格雷用药的可行性。方法横断面研究。筛选2019年8月至2023年12月徐州市中心医院收治且进行了CYP2C19基因POCT的1084例HR-NICE患者(男性678例,占比62.5%),其中198例同时进行了CYP2C19基因的传统血液检测,比较两种检测方法的结果和用时并对POCT结果进行分析。结果198例患者POCT与传统血液检测的CYP2C19基因型一致率为99.0%,配对χ^(2)检验结果显示两种检验方法的CYP2C19^(*)2和^(*)3基因型结果差异无统计学意义(均为P>0.05)。POCT比血液检测的用时更短(P<0.01)。POCT结果显示,不同代谢类型患者的年龄、性别差异无统计学意义(均为P>0.05),而CYP2C19^(*)2和^(*)3基因型差异有统计学意义(均为P<0.001)。结论GMEX系统POCT是一种高效可行的CYP2C19基因分型方法,能够为HR-NICE治疗提供快速精准的用药指导。
Objective To compare the consistency of CYP2C19 genotyping between the point-of-care testing(POCT)using the GMEX system and blood testing and evaluate the feasibility of POCT technology in rapidly guide clopidogrel medication for patients with high-risk non-disabling ischemic cerebrovascular events(HR-NICE).Methods Cross-sectional study.A total of 1084 HR-NICE patients(678 males,accounting for 62.5%)admitted to Xuzhou Central Hospital from August 2019 to December 2023 and underwent POCT CYP2C19 genotyping were selected.Among them,198 patients also underwent blood-based CYP2C19 genotyping.The results and time consumption of both testing methods were compared,and the POCT results were analyzed.Results Among the 198 patients,the concordance rate of CYP2C19 genotypes between POCT and conventional blood testing was 99.0%.Pairedχ^(2) test results showed no statistically significant differences in CYP2C19^(*)2 and^(*)3 genotypes between the two testing methods(all P>0.05).POCT required shorter time than blood testing(P<0.01).POCT results revealed no statistically significant differences in age or gender among patients with different metabolic types(all P>0.05),while CYP2C19^(*)2 and CYP2C19^(*)3 genotypes exhibited statistically significant differences(all P<0.001).Conclusions POCT using the GMEX system is an efficient and feasible method for CYP2C19 genotyping,which can provide rapid and accurate medication guidance for the treatment of HR-NICE.
作者
王琛
陈国芳
刘薇薇
徐辉
周晓亚
韦家南
张文丽
Wang Chen;Chen Guofang;Liu Weiwei;Xu Hui;Zhou Xiaoya;Wei Jianan;Zhang Wenli(Department of Neurology,Xuzhou Central Hospital,Xuzhou Clinical College of Xuzhou Medical University,Xuzhou 221009,China;Graduate School of Bengbu Medical College,Bengbu 233030,China)
出处
《中国心血管杂志》
北大核心
2025年第6期692-696,共5页
Chinese Journal of Cardiovascular Medicine
基金
徐州市医学领军人才培养项目(XWRCHT20210037)
江苏省干部保健科研课题(BJ20007)
江苏省新药研究与临床药学重点实验室开放研究课题(XZSYSKF2020022)
徐州市科技项目(KC21213)
徐州市卫生健康委科技项目(XWKYHT20220162)。
